ALSO NOTED: Byetta data backs stand-alone app; Watson, Novartis settle suit;

> Amylin Pharmaceuticals says it has the data to back an application to make Byetta a stand-alone therapy for diabetes. Report

> Watson and Novartis have settled their patent wrangle over the Alzheimer's drug Exelon. Report

> We're happy the way we are, thank you very much. That's what Genzyme CEO Henri Termeer (photo) has to say to rumors that the company could be next on the list of Big pharma biotech buyouts. Report

> In yet another sign of monoclonal antibodies' popularity among big drug developers, Wyeth has extend its evaluation of selected Raven Biotechnologies MAb antibodies. Report

And Finally…. Stand and deliver…smiles. A new survey shows parents prefer teachers who make their children happy over teachers with high achievement ratings. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.